As awareness of obstructive sleep apnea continues to grow across Central Ohio, Sleep Better Columbus has announced an expansion of its oral appliance therapy offerings to better serve individuals ...
Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI ...
Please provide your email address to receive an email when new articles are posted on . Achievement of an apnea-hypopnea index less than 10 events per hour signaled obstructive sleep apnea resolution.
The once-daily oral drug improves patients’ lives while maintaining early, durable, and central nervous system responses, ...
In a phase 2b clinical trial, an investigational oral therapy called PrimeC was found to be safe and well tolerated in people ...
A panelist discusses how oral combination therapy with decitabine-cedazuridine plus venetoclax shows activity in the relapsed/refractory acute myeloid leukemia setting, achieving responses even in ...
In a phase 2b trial, nearly 100% of patients treated with SAP-001 at the 30mg and 60mg doses achieved the target serum uric acid level of less than 6mg/dL. The Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results